Results 151 to 160 of about 12,163 (174)

Gastrointestinal Bleeding With Edoxaban Versus Warfarin

Circulation: Cardiovascular Quality and Outcomes, 2018
Background: The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban
Jeffrey Weitz, Eugene Braunwald, Michele Mercuri   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Edoxaban

Reactions Weekly
  +13 more sources

Edoxaban

Reactions Weekly, 2023
  +7 more sources

Edoxaban Tosylate

American Journal Cardiovascular Drugs, 2011
Daiichi Sankyo is developing edoxaban tosylate (DU 176b; DU-176; DU-176b; DU176b) as an orally active direct factor Xa inhibitor for the prevention of stroke and the prevention and treatment of venous thromboembolism. Two dosing regimens of edoxaban tosylate are being compared with warfarin over 24 months in the ENGAGE AF TIMI 48 trial (NCT00781391) in
openaire   +2 more sources

Edoxaban

Reactions Weekly, 2022
  +4 more sources

Edoxaban

Reactions Weekly, 2019
  +6 more sources

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Circulation, 2017
Christian Ruff, Giulia Renda
exaly  

Edoxaban in Asian Patients With Atrial Fibrillation

Journal of the American College of Cardiology, 2018
Kyungdo Han
exaly  

Edoxaban affects TRAP-dependent platelet aggregation

Journal of Thrombosis and Thrombolysis, 2020
Marian Mokan, Juraj Sokol, František Nehaj   +2 more
exaly  

Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan

Journal of Arthroplasty, 2014
T Fuji, C -J Wang, C-J Wang
exaly